NO2 inhalation promotes Alzheimer’s disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication
College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China
Abstract
Air pollution has been reported to be associated with increased risks of cognitive impairment and neurodegenerative diseases. Because NO2 is a typical primary air pollutant and an important contributor to secondary aerosols, NO2-induced neuronal functional abnormalities have attracted greater attention, but the available experimental evidence, modulating mechanisms, and targeting medications remain ambiguous. In this study, we exposed C57BL/6J and APP/PS1 mice to dynamic NO2 inhalation and found for the first time that NO2 inhalation caused deterioration of spatial learning and memory, aggravated amyloid β42 (Aβ42) accumulation, and promoted pathological abnormalities and cognitive defects related to Alzheimer’s disease (AD). The microarray and bioinformation data showed that the cyclooxygenase-2 (COX-2)-mediated arachidonic acid (AA) metabolism of prostaglandin E2 (PGE2) played a key role in modulating this aggravation. Furthermore, increasing endocannabinoid 2-arachidonoylglycerol (2-AG) by inhibiting monoacylglycerol lipase (MAGL) prevented PGE2 production, neuroinflammation-associated Aβ42 accumulation, and neurodegeneration, indicating a therapeutic target for relieving cognitive impairment caused by NO2 exposure.
Article notes
Untitled section
Received 2015 Nov 17; Accepted 2016 Feb 15; Collection date 2016.
Alzheimer’s disease (AD) is a common neurodegenerative disease that is becoming more prevalent in aging populations worldwide, and of the various diseases involving neurological dysfunction, AD is the only disease that has presented increased mortality over the last decade. The Alzheimer’s Association projects that unless a cure or preventative treatment is discovered, by 2050, the number of people with AD is projected to increase from more than 6 million people currently to approximately 20 million in China, from more than 5 million to approximately 16 million in the United States, and from nearly 44 million to at least 115 million worldwide1,2. The disease is characterized by the excessive deposition of β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain, and the pathological progression is accompanied by neuroinflammation, synaptic dysfunction, progressive cognitive deficits, and memory loss associated with widespread nerve cell death3. Because AD is persistent, disabling and costly, the disease can severely strain health-care systems. Although the predicted increase in the frequency of AD is mainly due to population aging, other common risk factors have been proposed, including familial inheritance, ApoE polymorphisms, sex, coexistence with other disorders (such as cardiovascular diseases, brain damage, diabetes and Down syndrome), and certain environmental factors4,5. Importantly, increasing numbers of epidemiological studies have demonstrated strong links between exposure to air pollution and increased AD-related morbidity6,7,8,9.
Air pollution is resulted from a complex mixture of pollutants consisting of both particle and gas components. The identification of the specific pollutants that contribute most to health hazards could play an important role in the creation of environmental and social policies, with crucial implications for the actions taken by local authorities to reduce exposure and the risks of pollutants to public health. In this field, an important pollutant that contributes to health hazards is NO2, which is usually considered to constitute most of the atmospheric burden of nitrogen oxides (NOx)10. As reported, peak levels of up to 0.4–4 parts per million (ppm) have been encountered in the outdoors, particularly along the curbsides in downtown areas with heavy motor vehicle traffic11. Indoor concentrations of NO2 often exhibit much higher levels than those usually found outdoors, in garages, on ferries, at ice skating rinks, and in kitchens with gas ovens, NO2 levels can be as high as 4 ppm12. Therefore, NO2 has been confirmed as a strong indicator of outdoor and indoor air quality and a potential novel risk factor for negative health effects. In addition to traditional respiratory damage, recent epidemiological studies have linked NO2 pollution to an increased risk of neurological disorders, including abnormalities in general cognitive scores, on psychomotor, attention and sensory scales, and in logical memory among preschool children, middle-aged and older adults and populations exposed to occupational traffic (policemen and drivers)13,14,15,16,17. Whereas cognitive impairment is a clinical manifestation of many neurological diseases, it has also been termed a prodromal stage of AD that occurs in the pre-clinical phase18. People with mild cognitive impairment (MCI) have an increased risk of eventually developing AD or another type of dementia, with a rate of progression between 10% and 15% per year19. This information indicates that exposure to NO2 in outdoor and indoor air environments might contribute to cognitive deficits and could accelerate AD-like progression.
The real air environment is a complex system that contains various components, some of which are more plausible toxicants. Therefore, due to the different components in the mixture of air pollutants, epidemiological evidence might be insufficient to confirm the exposure-response correlation between NO2 and AD progression, particularly regarding the evidence from exposure markers and molecular targets. In the present study, we dynamically exposed C57BL/6J and APP/PS1 mice to NO2 at 2.5 and/or 5 mg/m3 (5 h/day, approximately one-hour average concentration every day 0.52 and 1.04 mg/m3), and the concentration did not exceed the permissible exposure limit of a time-weighted average concentration from National Institute for Occupational Safety and Health (NIOSH, 1.8 mg/m3), was about 2.17 or 4.33 times higher than the one-hour average concentration limit of national air quality secondary standards from China (0.24 mg/m3), and was about 2.77 or 5.53 times higher than the one-hour standard set of National Ambient Air Quality Standard (NAAQS) from the U. S. Environmental Protection Agency (EPA, approximately 0.188 mg/m3). Following the inhalation exposure, we found that NO2 air pollution poses a potential risk by promoting AD-like pathological and functional abnormalities, revealing a mechanistic basis for treating, ameliorating, or preventing AD-related outcomes in polluted areas.
Results
NO2 inhalation deteriorates spatial learning and memory and potentiates amyloid production
To determine whether NO2 inhalation impaired cognitive function and caused AD-like pathological abnormalities, we exposed normal C57BL/6 J mice to 2.5 and 5.0 mg/m3 NO2 via dynamic inhalation. For the first time, we observed changes in spatial learning and memory: NO2 inhalation caused dose-dependent impairment of mouse performance on the Morris water maze test, and compared to control animals, NO2-exposed mice required a longer time to find the hidden platform (Fig. 1a). In a probe trial, the number of mice crossing the target zone and the time the mice stayed in the target quadrant were reduced in a dose-dependent manner, and a significant difference was observed after inhalation of 5 mg/m3 NO2 (Fig. 1b,c).
Progressive memory loss and cognitive decline are believed to be promoted by Aβ-induced damage, which plays a major causative role in AD pathogenesis3. Aβ peptides are derived from the sequential cleavage of amyloid precursor protein (APP), and the enzymatic hydrolysis is primarily mediated by β-site APP cleaving enzyme 1 (BACE1). Among a diverse group of Aβ peptides that vary in length depending on the specific cleavage site, the 42-residue-long form (Aβ42) is the most pathogenic structure20. To provide pathological evidence of the deterioration of spatial learning and memory due to NO2, we further detected the expression of proteins related to Aβ synthesis and the deposition of Aβ42. As shown in Fig. 2a and b, inhalation of 5 mg/m3 NO2 slightly but significantly elevated APP and BACE1 expression in both the cortex and the hippocampus, and it selectively caused Aβ42 deposition (see Fig. 2c; significant accumulation of Aβ42 in 2 animals were observed based on 5 animals in response to 5 mg/m3 NO2 inhalation). These results indicated that NO2 inhalation could potentiate Aβ42 production and contribute to the deterioration of spatial learning and memory.
NO2 inhalation aggravates cognitive deficits and amyloid deposition in APP/PS1 mice
If the above indications were correct, there should be a link between NO2 inhalation and AD progression. Therefore, NO2 inhalation should aggravate the pathological abnormalities and cognitive deficits of APP/PS1 transgenic mice. Considering that APP/PS1 animals develop amyloid plaques beginning at the age of 5–6 months21, to test this hypothesis, we treated 5-month-old APP/PS1 transgenic mice with NO2 (5 mg/m3) for 4 weeks, followed by an investigation of their spatial learning and memory and related pathological alterations. As shown in Fig. 3, NO2-exposed animals exhibited longer latency, fewer crossings of the target zone, and a shorter time in the target quadrant. Importantly, we observed significant aggravation of Aβ42 accumulation and deposition in the cortical and hippocampal regions after NO2 inhalation (Fig. 4a,b). Because neurodegenerative change is an important feature of the neuropathology of MCI and AD, we further assessed whether NO2 inhalation could exacerbate neurodegeneration in the AD model mice. The results indicated that NO2 exposure significantly increased the number of FJC-positive neurons (Fig. 4c), which substantiated the notion that NO2 inhalation aggravated Aβ deposition, worsened cognitive deficits, and contributed to AD progression.
Cyclooxygenase-2 (COX-2)-mediated arachidonic acid metabolism participates in NO2 aggravation of AD progression
To clarify the potential modulatory mechanisms by which NO2 inhalation exacerbates AD progression, gene chip analysis was performed in APP/PS1 mouse brains before and after NO2 exposure. In total, 5,487 significantly differentially expressed genes were identified (P < 0.01). Then, we investigated the regulatory potential of these target genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Biocarta pathways; the items associated with neurological disorders are presented in Fig. 5a. These results indicated that the genes that significantly changed after NO2 inhalation are mostly involved in synaptic function and learning and memory abilities, including long-term potentiation/depression (LTP/D), the nitric oxide signaling pathway, glutamatergic synapses, neurotrophin signaling, and the calcium signaling pathway. Additionally, the generation of Aβ peptide by PS1, a platelet amyloid pathway protein and an early indicator of AD, revealed Aβ peptide production and deposition-derived AD pathogenesis after NO2 treatment. These results provided further evidence that NO2 inhalation contributed to the deterioration of spatial learning and memory and potentiated AD-like amyloid pathology.
These phenomena led to a crucial issue pertaining to the molecular regulatory mechanism involved in these effects. Intriguingly, the KEGG pathway analysis revealed the involvement of arachidonic acid (AA) metabolism. AA-derived prostaglandin E2 (PGE2), which arises mainly from the cyclooxygenase-2 (COX-2) reaction, is an important mediator that stimulates Aβ formation, promotes neuroinflammatory responses, and modulates synaptic events22,23. Therefore, it appears that COX-2-mediated AA metabolism is a possible mechanism by which NO2 promotes AD progression. The genes in the AA metabolism pathway that significantly changed are presented in Fig. 5b and Table 1. Among these genes, ptgs2 (also known as cox-2) was up-regulated after NO2 inhalation (1.26- fold of control levels) suggesting the involvement of COX-2-derived PGE2 synthesis. To provide additional evidence for this relationship, we determined the levels of AA and PGE2 and the COX-2 expression in the cortex. As shown in Fig. 6a–c, the principal metabolic effects after NO2 inhalation were a reduction in AA levels and an increase in PGE2 production accompanied by significant COX-2 elevation. COX-2-mediated production of PGE2 is a known inflammatory mediator that enhances the neuroinflammatory response, which is involved in the complex cascade and contributes to synaptic and cognitive deficits in AD24. Subsequently, we used specific markers (OX42/CD11b and GFAP) in APP/PS1 animals to determine the activation of microglia and reaction of astrocytes before and after NO2 exposure. As shown in Fig. 6d and e, obvious increases in CD11b and GFAP expression occurred in the cortex and hippocampus, indicating amplified neuroinflammation following NO2 inhalation. These findings indicated that COX-2-mediated conversion of AA into PGE2 played a key role in NO2-mediated aggravation of AD progression.
| Gene ID | Symbol | P values | Fold change | Official Full Name |
|---|---|---|---|---|
| 11686 | alox12b | 1.0E-4 | 1.4025 | glutathione peroxidase 7 |
| 12408 | cbr1 | 2.37E-05 | 1.2371 | carbonyl reductase 1 |
| 70101 | cyp4f16 | 0.0039 | 0.8822 | cytochrome P450, family 4, subfamily f, polypeptide 16 |
| 72303 | cyp2c65 | 0.0024 | 0.6485 | cytochrome P450, family 2, subfamily c, polypeptide 65 |
| 74519 | cyp2j9 | 0.003 | 0.9182 | cytochrome P450, family 2, subfamily j, polypeptide 9 |
| 67305 | gpx7 | 0.0022 | 0.8851 | glutathione peroxidase 7 |
| 66350 | pla2g12a | 0.0005 | 0.8603 | phospholipase A2, group XIIA |
| 19225 | ptgs2 | 0.0021 | 1.2576 | prostaglandin-endoperoxide synthase 2 |
| 96979 | ptges2 | 0.0009 | 0.8691 | prostaglandin E synthase 2 |
| 21391 | tbxas1 | 0.0087 | 0.8167 | thromboxane A synthase 1, platelet |
MAGL disruption suppresses COX-2-derived PGE2 and restores AD-like pathology and cognitive deterioration in response to NO2 inhalation
In this manner, if the COX-2-mediated conversion of AA into PGE2 modulates NO2-induced neuronal dysfunction, COX-2 inhibition should be the most effective method for relieving these injuries. However, the occurrence of serious side effects, such as the gastrointestinal toxicity of nonselective COX-2 inhibitors and the cardiovascular risk caused by selective COX-2 inhibitors, has limited their translational potential for neuroinflammatory syndromes25 and has promoted the search for novel medications. To address this problem, the experimental findings that 2-arachidonoylglycerol (2-AG) protects neurons from inflammation- and neurodegeneration-induced damage has attracted our focus to endocannabinoids (eCBs). A growing body of evidence indicating the antioxidant, anti-inflammatory and neuroprotective properties of eCBs has recently accumulated26,27,28,29. Although still preliminary, the modulation of eCBs could constitute an innovative therapeutic approach for the treatment of AD. As the most abundant endocannabinoid in the brain, 2-AG is produced mainly from diacylglycerol (DAG) by diacylglycerol (DGL) lipase, and it is hydrolyzed to AA by monoacylglycerol lipase (MAGL). MAGL plays a major role in the regulation of 2-AG levels, and its inhibition elevates endogenous 2-AG and decreases the production of AA and downstream AA-derived eicosanoids. Importantly, endogenous 2-AG also suppresses the excessive expression of COX-230. This information was revealed by the available medications for neuroinflammatory and neurodegenerative diseases, and MAGL is considered to be a potential target. Therefore, we hypothesized that strengthening endogenous 2-AG by inhibiting MAGL could prevent neuronal insults and relieve the subsequent NO2 inhalation-induced cognitive deficits by limiting COX-2-derived PGE2 production. To test this hypothesis, we exposed C57BL/6 J mice to 5 mg/m3 NO2 in the absence or presence of pre-treatment with JZL184, a highly selective and potent MAGL inhibitor, and we detected the AA and PGE2 levels, COX-2 expression, and neuroinflammation in the brain. The results indicated that NO2 inhalation elevated MAGL and COX-2 expression and caused significant AA reduction, PGE2 elevation, and obvious activation of astrocytes and microglia. However, the chemical exposure did not alter 2-AG content (see Fig. 7a). Importantly, pre-treatment with the MAGL inhibitor JZL184 significantly augmented the levels of endogenous 2-AG and AA, attenuated PGE2 release, and alleviated neuroinflammation in the brain following NO2 inhalation. These findings indicated that increasing the levels of the endocannabinoid 2-AG by disrupting MAGL prevented the COX-2-derived conversion of AA into PGE2 and neuroinflammation resulting from NO2 exposure.
If COX-2-derived PGE2 signaling modulates the NO2-mediated aggravation of AD progression and if MAGL inhibition prevents the PGE2 release after the COX-2-mediated conversion of AA, MAGL disruption should suppress Aβ accumulation and reverse cognitive deterioration following exposure to NO2. Following this logic, we further determined the alterations in Aβ42 accumulation and neurodegeneration. As presented in Fig. 8, JZL184 significantly reduced NO2-induced APP and BACE1 elevation, Aβ42 deposition, and neurodegeneration. To determine the functional outcomes of APP and BACE1 elevation in response to MAGL inhibition, we detected the changes in cognitive function and found that JZL184 also significantly reversed the NO2-induced impairment of spatial learning and memory (Fig. 9). Reports have shown that PGE2 could significantly elevate APP expression by activating EP2/EP4 receptors, thus leading to the accumulation of Aβ31. Therefore, these results indicated that the elevation of endogenous 2-AG levels via MAGL disruption prevented COX-2-mediated PGE2 production, reduced the neuroinflammation-associated accumulation of Aβ42, and ameliorated subsequent cognitive impairment in response to NO2 inhalation.
Discussion
AD has become a major public health concern as the world’s population ages. It has been estimated that in 2015, there were more than 40 million persons worldwide living with dementia and the global incidence of AD is expected to double in the next 20 years2. Emerging evidence has indicated that air pollution elevates markers of brain inflammation and contributes to the risk of Alzheimer’s-type neurodegenerative disease. NO2 is an important air pollutant arising mainly from anthropogenic emissions, and the global NO2 map measured by Aura’s Ozone Monitoring Instrument (OMI) has indicated that Asia has been among the noticeable hot spots of pollution in the last decade due to population increases and the industrialization of Asian countries32. Unfortunately, by the middle of the century, the Asia Pacific region will have more than half of the total number of people with dementia worldwide33. Because NO2 inhalation promotes AD-like pathologies and cognitive deficits, including AD progression, there is a pressing need to understand the molecular ways in which AD develops in NO2-polluted areas. This understanding could be a critical step in identifying biomarkers that predict future clinical symptoms and can be used as outcome measurements in clinical trials of disease-modifying agents targeted at efficiently halting or reversing neurological disorders.
Here, we found for the first time that NO2 inhalation causes the deterioration of spatial learning and memory and tends to promote Aβ deposition in a concentration-dependent manner. Importantly, NO2 aggravated cognitive impairment, amyloid deposition, neuroinflammation and neurodegeneration in APP/PS1 model mice. AD is characterized by progressive neurodegeneration, and neurofibrillary degeneration and neuroinflammation are prominent features of the disease3. Early versions of the amyloid cascade hypothesis of AD posited that Aβ peptide deposition triggered inflammation, tau hyperphosphorylation, synapse damage and neuronal loss, which were considered causal of cognitive decline34. Our findings confirmed the relationships between air NO2 exposure and the neuropathological responses typically associated with AD in vivo.
Air pollution is a multifaceted toxic chemical mixture capable of assaulting the central nervous system (CNS). A coherent pathway linking exposure to air pollution and brain damage includes a chronic inflammatory process involving the respiratory tract, which results in a systemic inflammatory response with the production of inflammatory mediators capable of reaching the brain; continuous expression of crucial inflammatory mediators in the CNS at low levels; and the formation of oxidative species (ROS)35. Considering our previous study that acute NO2 inhalation induces the release of proinflammatory elements, including tumor necrosis factor-α (TNF-α), interleukin-1β (Il-1β) levels and intercellular adhesion molecule 1 (ICAM-1) in rat lung and heart, causing the elevation of reactive ROS and induced excessive expression of cytokines TNF-α and Il-1β in rat cortex36,37,38, we speculated that NO2 exposure may causes pro-inflammatory signals originating in peripheral tissues/organs including the lung and the cardiovascular system, giving rise to a systemic-induced cytokine response that transfers inflammation to the brain. However, the specific molecular mechanism regulated NO2-induced neuronal insults has remained unclear. To address this issue, we first performed a whole gene sequence analysis in APP/PS1 animals before and after NO2 exposure. Based on the genes that were significantly changed, KEGG and Biocarta pathway graphing not only confirmed AD pathology and cognitive impairment, but also suggested a potential modulating process. COXs are the key rate-limiting enzymes that determine the first two steps in the biosynthesis of PGs from AA. Importantly, COX-2-mediated PGE2 production is initiated by an ROS attack and has been implicated in synaptic signaling and certain neurologic abnormalities, such as traumatic brain injury, stroke, epilepsy and AD39. Therefore, AA metabolism and the elevation of ptgs2, which catalyze the synthesis of PGE2, attracted our attention. Interestingly, we found COX-2 elevation, AA reduction, excessive PGE2 production and subsequent neuroinflammation in APP/PS1 mice after NO2 exposure, and we confirmed these results in APP/PS1 and C57BL/6 J mice. These findings indicated that the COX-2-derived conversion of AA into PGE2 might be a key modulator in NO2-mediated aggravation of AD progression.
The human epidemiological literature has shown elevated levels of PGE2 in the cerebrospinal fluid of early-stage AD patients40. Additionally, research performed in AD model mice has shown that individual PGE2 G protein-coupled receptors contribute to the development of AD, and global deletion of these receptors reduces amyloid pathology41. By contrast, Aβ is produced by proteolysis of APP by β- and γ-secretases and characterizes AD pathogenesis. Previous in vivo and in vitro experiments have indicated that PGE2 release stimulates APP expression via EP2/EP4 receptors in parallel with Aβ deposition, ultimately resulting in AD pathogenesis31. Consistent with these results, our present data showed that APP and BACE1 expression and Aβ42 deposition were significantly augmented in response to COX-2 over-expression and PGE2 elevation following NO2 inhalation. Moreover, NO2 inhalation exacerbated the weakening of spatial learning and memory in APP/PS1 mice. It has been reported that NO2 is a typical indicator of traffic-related atmospheric pollution, and the increasing severity and duration of traffic congestion have greatly increased NO2 emissions. In addition, several studies have shown that traffic exhaust might be neurotoxic and could be expected to promote CNS dysfunction, which could manifest as cognitive deficits42. Reports from Mexico City have revealed that serious air pollution stimulates nuclear factor-κB activation and nitric oxide generation contributing to the increased release of the pro-inflammatory markers IL-1β and TNF-a in animal brains. Moreover, pollution has been associated with COX-2 up-regulation and Aβ42 deposition in human autopsies43,7. Consistent with these results from previous studies, our present findings provided further evidence that the COX-2-catalyzed production of PGE2 participated in NO2-induced AD-like neurological dysfunction, indicating that COX-2-mediated PGE2 generation could be used as a predictive marker of the clinical symptoms associated with cognitive dysfunction in NO2-exposed individuals.
Based on this information, the next critical step was to determine the pathways that can be efficiently targeted to halt or reverse these neurological outcomes. Non-steroidal anti-inflammatory drugs (NSAIDs) are effectively reducing neurotoxicity and have been associated with neuronal protection. The best-characterized actions of NSAIDs are their anti-inflammatory properties, which are exerted primarily through their irreversible inactivation of the COX enzyme to limit the production of pro-inflammatory PGs. In particular, previous studies have indicated that COX-2-selective inhibitors, a typical type of NSAIDs, suppress COX-2-derived PGE2 signaling and prevent neuronal insults and AD development44. Based on these findings, COX-2-selective inhibitors, including SC-58125, celecoxib, and NS398, should target NO2-induced PGE2 signaling and neurological dysfunction. Because these medications are already available, they could potentially be used to prevent and treat injuries in polluted areas. However, COX-2-selective inhibitors can also increase blood pressure, induce or worsen cardiac failure, and impair kidney function to the point of renal failure even though these inhibitors do not induce the gastric ulcerations associated with the use of traditional NSAIDs45. These unexpected side effects have limited their medical use in certain markets. Therefore, we must find novel approaches for inhibiting COX-2-derived PGE2 signaling and to relieve AD-like progression following NO2 inhalation. The eCB system, which acts on demand to confer neuroprotection, has received a fair amount of attention over the past few years. Among the identified eCBs, 2-AG is bioactive and abundant in the brain that is well known for its significant functions in synaptic modification, the resolution of neuroinflammation and neuronal survival30,46. Importantly, the anti-inflammatory and neuroprotective effects of 2-AG appear to be realized by suppressing the activity and expression of COX-2 that occur in response to harmful insults47. This information suggests that strengthening 2-AG signaling might be a safe and effective way to limit the COX-2-derived PGE2 pathway following NO2 exposure. As one of the most studied eCBs, 2-AG is mainly synthesized from DAG by DGL and is hydrolyzed to AA by MAGL. MAGL is responsible for approximately 85% of brain 2-AG hydrolytic activity, and MAGL disruption enhances the endogenous levels of 2-AG and provides beneficial effects in resolving ongoing inflammation in the brain, which is the root of many neurodegenerative diseases48. As such, in the present study, we chose to investigate whether MAGL inhibition had neuroprotective effects on NO2-induced AD-like symptoms.
Here, we raised endogenous 2-AG levels by applying the selective MAGL inhibitor JZL184, providing convincing evidence that MAGL inhibition elevates brain 2-AG levels and blocks AA metabolism by suppressing COX-2 expression and PGE2 release. These findings suggested that the increased levels of endogenous 2-AG resulting from MAGL inhibition were sufficient to restore the negative neurological effects caused by NO2. Additionally, the NO2-mediated elevation of APP expression and PGE2-stimulated Aβ42 production were significantly reduced by endogenous 2-AG-induced inhibition of COX-2. Aβ is the initiator of AD pathogenesis, which is also prominently featured in neuroinflammation that occurs in association with activated microglia and reactive astrocytes, neuronal degeneration, and synaptic dysfunction49. In the present study, NO2 inhalation destroyed the functional normality of synaptic transmission by altering the glutamatergic synaptic and LTP/D pathway, enhancing microglial and astrocyte activation and increasing neuronal degeneration, ultimately causing learning and memory disorders. Importantly, MAGL inhibition relieved the NO2-induced aggravation of the classical neuropathological changes related to AD in vivo, including the attenuation of neuroinflammation and neurodegeneration and the restoration of spatial learning and memory. Thus, we propose that elevating endogenous 2-AG by inactivating MAGL has beneficial effects on suppressing COX-2-derived PGE2 signaling and thereby contributes to treating, ameliorating, or preventing AD-like progression in NO2-polluted areas.
In summary, NO2 inhalation deteriorated spatial learning and memory, potentiated Aβ production, and contributed to AD progression. These actions appear to be mediated by the COX-2-derived AA metabolism of PGE2. Furthermore, strengthening the endogenous 2-AG levels via MAGL disruption effectively inhibited the neuroinflammation and Aβ accumulation induced by the excessive release of PGE2, thereby restoring impaired spatial learning and memory in response to NO2 inhalation (Fig. 10). These findings emphasized the potential risks of NO2 in indoor and outdoor air environments, as NO2 accelerates AD-like neurodegenerative diseases. Finally, these results revealed a mechanistic basis for treating, ameliorating, or preventing AD-related outcomes in polluted areas.
Methods
Animals
Male C57BL/6 J mice and APPswe/PS1dE9 (APP/PS1) transgenic mice were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, PRC) and were housed in the animal research room at Shanxi University. The animals were maintained in plastic cages on a 12-h light cycle with standard laboratory food and water. For exposure, C57BL/6 J mice (approximately two months old) were randomly divided into three groups (n = 25 mice per group), and APP/PS1 mice (approximately five months old) were divided into two groups (n = 15 mice per group). Then, the NO2-inhaling animals were placed in a dynamic inhalation chamber and exposed to 2.5 or 5.0 mg/m3 NO2 for 5 h/day for 4 weeks. Accordingly, the control mice were exposed to room air in an identical chamber on the same schedule. The desired concentration was obtained by mixing NO2 gas with fresh air at the intake port of the chamber, and the diluted gas was evenly distributed across the whole chamber by two perforated gas radiant plates, with one located in the intake port and the other connected to a gas outlet matched with an aspirator pump. A real-time NO2 monitor (Wandi, China) was used to detect the concentration of NO2 in the exposure chamber. For the MAGL interference experiments, C57BL/6 J mice (approximately two months old) were divided into three groups (n = 25 mice per group). The interference groups were intraperitoneally (i.p.) injected with JZL184 (8 mg/kg bw/2 days) and then were exposed to 5 mg/m3 NO2 (for 5 h/day for 4 weeks) 1.5 h after injection. The NO2 exposure group was i.p. injected with the vehicle solution, followed by 5 mg/m3 NO2 inhalationfor 5 h/day for 4 weeks. Correspondingly, the vehicle control animals received vehicle i.p. injection and were exposed to room air. All animal experiments were conducted in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee of Shanxi University.
Behavioral tests
Morris water maze (MWM) studies with mice have principally been performed to measure hippocampal-dependent spatial-based learning and memory. A circular tank with a diameter of 75 cm H × 100 cm was filled with water rendered opaque by the addition of white, non-toxic paint. A circular platform with a diameter of 15 cm was placed 1 cm below the water surface in the center of a specific quadrant of the tank. The animals were given training sessions using visible and invisible platforms for a period of 8 consecutive days (8 sessions in total). In the non-spatial MWM, the mice received 3 consecutive days of training to find the same platform elevated above the water surface. Then, submerged platform training, which consisted of 5 identical daily sessions with 4 trials per day, was conducted. For each trial, the mice were released from the wall of the tank with their faces in the water. The mice were given 60 s to locate the escape platform. If an animal failed to reach the platform within a fixed period of 60 s, it was gently guided to the location and was allowed to stay on it for 10 s. For each training session, the sequence designed for the animals’ training was determined in a random manner that varied each day so that it was different between the separate sessions for each animal and was different for individual animals. Using an Etho Vision video tracking device (Noldus, Netherlands), we recorded the latency in reaching the target as task performance. The average latencies on each hidden platform training day were recorded and compared. Memory tests were conducted in a probe trial performed 24 h after the last training trail. A probe trial was performed in which the platform was removed from the tank and the animals were allowed to swim for 60 s. The number of target annulus crossovers and the time spent in the target quadrant were measured.
Immunoblots
Cortical or hippocampal tissue was weighed, homogenized and incubated for 30 min in RIPA buffer containing protease inhibitors. The homogenate was then centrifuged at 13,000 g for 10 min at 4 °C. Protein samples were separated on premade 4 – 12% SDS-PAGE gels and were transferred to PVDF membranes (Bio-Rad). After incubation with primary antibodies, including anti-Aβ42 (1:1,000, Invitrogen, USA), anti-BACE1 (1:200, Bioss, China), anti-APP (1:200, Bioss, China), anti-COX-2 (1:200, Cayman, USA), and anti-MAGL (1:200, Cayman, USA), overnight at 4 °C, the membranes were blotted with IR Dye 800 CW-conjugated secondary antibody (1:5000, LiCor Biosciences, USA) at room temperature for 1 h. The densitometry of the bands was scanned and measured using a LI-COR Odyssey Infrared Fluorescent System. The density of each band was quantified using Image-pro Express software, version 6.0 (Media Cybernetics, USA) and was normalized to the corresponding β-actin (1:1000, Cell Signaling, USA) value to account for variations in loading.
Immunohistochemistry
Immunohistochemical staining was performed to assess the distribution and morphology of amyloid plaques, microglia, and astrocytesin coronally sectioned brain slices. The mice were injected intraperitoneally with pentobarbitone and were subsequently transcardially perfused with heparinized saline and 4% paraformaldehyde in PBS. The tissue was fixed in 4% paraformaldehyde overnight and was transferred to 15% and 30% sucrose solutions in 0.01 M PBS. Dehydration was reached when the tissue sank to the bottom. Series of 40 μm coronal brain sections were prepared with a freezing vibratome and were kept in 0.1 M PBS. Immunostaining was performed on free-floating tissue slices using antibodies specific for Aβ42 (1:2,000, Invitrogen, USA), followed by incubation with secondary antibodies (1:5000, LiCor Biosciences, USA) specific to astrocytes (GFAP, 1:2,000, Abcam, USA) and microglia (OX42/CD11b, 1:200, Abcam, USA) and then by incubation with IR Dye 800CW-conjugated secondary antibody (1:5000, LiCor Biosciences, USA). After washing, the sections were incubated with 4′-6-diamidino-2-phenylindole (DAPI), a fluorescent stain that binds strongly to DNA, to label the cell nuclei. The stained sections were captured using fluorescent microscopy (Olympus ix71, Japan) and were analyzed and quantified using Image-pro Express software, version 6.0 (Media Cybernetics, USA).
Histochemistry
Neurodegeneration was evaluated by Fluoro-Jade C (FJC) stainingaccording to the modified manufacturer’s protocol (Millipore, CA, USA). Cryostat-cutbrain sections were incubated in the dark with FJC (0.0001% solution of FJC dye) dissolved in 0.1% acetic acid for 10 min and then were incubated in DAPI (0.5 μg/mL) for 10 min. Subsequently, the slides were washed 3 times for 1 min each with distilled water, air-dried and coverslipped in the dark. The FJC-stained sections were examined under a fluorescence microscope (Olympus ix71, Japan), and imaging data were analyzed and quantified using Image-pro Express software, version 6.0 (Media Cybernetics, USA).
Liquid chromatography-tandem mass spectrometry
2-AG and AA were quantified in the brain tissues of C57BL/6 J mice and APP/PS1 transgenic mice using high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The quantification of 2-AG and AA was based on an external standard curve diluted with methanol. All the standards of the analytes were provided by Cayman Chemical (Ann Arbor, MI, USA). The brain tissue was weighed and extracted individually. Frozen samples were placed in extraction solvent containing 2 mL of acetonitrile in a borosilicate glass tube. After rapid homogenization, the sample was centrifuged at 1,500 g for 10 min. The supernatant was collected and evaporated to dryness under a gentle stream of nitrogen. Then, 200 μL of methanol were added to the extract, which was dried under N2 gas. Subsequently, the lipid extract was resuspended using 20 μL of methanol, and 5 μL were injected for LC-MS/MS analysis. A Waters UPLC system coupled with a triple quadrupole Quattro Premiere/XE mass spectrometer (Waters, USA) was used for the analysis. Liquid chromatography was performed using a Waters XSelect CSH C18 column 2.1 × 75 mm, 2.5 μm (Waters, USA), with 0.1% formic acid (A) and 100% acetonitrile (B) as a mobile phase. A flow rate of 400 μL/min was used for gradient elution, which started at 50% B, linearly increased to 90% at 2 min and was subsequently reequilibrated at 50% B for a further 2 min after a 4-min hold. The column temperature was 45 °C. The samples were kept at 4 °C in the autosampler until analysis. The targeted LC-MS/MS analysis was performed in multiple reaction monitoring mode (MRM) using the following transitions: the ESI + MRM transition for 2-AG was 379.4 > 287.3, and the ESI- MRM transition for AA was 303.3 > 259.1. The amounts of 2-AG and AA were calculated from the ratios of peak areas of compounds to external standards and by comparing the results with standard curves.
PGE2 assay
PGE2 content was measured using the Prostaglandin E2 EIA Kit (Cayman, USA). Briefly, 50 mg of cortical tissue were homogenized in 250 μL phosphate-buffered saline (0.1 M phosphate, pH 7.4, containing 1 mM EDTA and 10 μM indomethacin) and then were centrifuged for 10 min at 8,000 g. The supernatant was collected, diluted 1:500 with enzyme immunoassay buffer, and assayed per the protocol in the kit.
Genechip array
RNA was extracted from approximately 50 mg of hippocampal tissues, and the collected tissues were immediately flash frozen in liquid nitrogen. Total RNA was extracted using TRIZOL Reagent (Life Technologies, USA) according to the manufacturer’s instructions. The RNA integrity number (RIN) was checked using an Agilent Bioanalyzer 2100 (Agilent Technologies, USA) to ensure RNA integration. The RNeasy Mini Kit and RNase-Free DNase Set (Qiagen, Germany) were used for the purification of qualified total RNA. Samples were selected randomly from 4 mice per group and pooled for subsequent microarray analysis. Gene expression analysis was performed using the Agilent one-color Gene Expression Platform. A total of 8 separate arrays from the Agilent mouse 4 × 44k Chip were conducted for the analysis of pooled total RNA samples from the control and NO2 treatment groups. The protocol was performed according to the manufacturer’s instructions.
Gene expression and pathway analysis
Microarray slides were scanned using an Agilent Microarray Scanner (Agilent Technologies, USA) with the default settings (dye channel: green; scan resolution: 5 μm; PMT 100%; 10%; 16 bit). The data were extracted from the raw microarray image files using Feature Extraction Image Analysis software, version 10.7 (Agilent Technologies, USA). Significant changes in gene expression were represented using DIFF Pval (P value, P < 0.05 was considered statistically significant). In the present study, we evaluated the differentially expressed genes with significance of P < 0.01. Because the expressions of several genes were significantly altered in response to NO2 exposure, pathway analysis was performed to determine the potential pathways in which the genes showing differential expression were involved. To better understand the underlying biological mechanisms involved, data files from APP/PS1 mice were submitted electronically to the Web-based tool Onto-Tools (http://www.shanghaibiotech.com/sas.html) available on the Shang Hai Biotechnology Corporation website (Shanghai, China). KEGG (Kyoto Encyclopedia of Genes and Genomes) and Biocarta are two knowledge bases for linking genomes to life through the process of pathway mapping. The pathway database consist graphical diagrams of biochemical pathways, including a variety of metabolic and regulatory pathways, our present results presented some specific selected and interested pathways in Fig. 5a.
Statistical analysis
The data are presented as the means ± S.E. Unless stated otherwise, statistical significance was assessed using one-way ANOVA with Fisher’s PLSD test among groups. Differences for all tests were considered significant when P < 0.05.
Additional Information
How to cite this article: Yan, W. et al. NO2 inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication. Sci. Rep. 6, 22429; doi: 10.1038/srep22429 (2016).
Supplementary Material
Acknowledgments
This study was supported by National Science Foundation of PR China (NSFC, No. 91543203, 21477070, 21377076, 21307079, 21222701), Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP, No. 20121401110003, 20131401110005).
Footnotes
Footnote Group
References
Untitled section
References
- Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 11, 332–384.
- Martin P. et al. World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer’s Disease International (ADI), London (2015).
- Michael W. et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 9, e111–e194 (2013).
- Moreno G. I., Lisbell D. E., Elisabeth S. M. & Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease. Nat. Commun. 4, 1495 (2013).
- Moulton P. V. & Yang W. Air pollution, oxidative stress, and Alzheimer’s disease. J. Environ. Public. Health. 2012, 1–9 (2012).
- Calderón-Garcidueñas L. et al. Environmental Air Pollution and Brain Damage. Toxicol. Pathol. 30, 373–389 (2002).
- Calderón-Garciduenãs L. et al. Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution. Toxicol. Pathol. 32, 650–658 (2004).
- Block M. L. & Calderón-Garcidueñas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends. Neurosci. 32, 506–516 (2009).
- Weuve J. et al. Exposure to particulate air pollution and cognitive decline in older women. Arch. Intern. Med. 172, 219–227(2012).
- Olsen D. B., Kohls M. & Arney G. Impact of oxidation catalysts on exhaust NO2/NOx ratio from lean-burn natural gas engines. J. Air. Waste. Manag.Assoc. 60, 867–874 (2010).
- Department of Health, Committee on the Medical Aspects of Air Pollutants. Asthma and Outdoor Pollution. HMSO, London (1995).
- Pathmanathan S. et al. Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5, IL-10, IL-13, and ICAM-1 in the bronchial epithelium of healthy human airways. Occup. Environ. Med. 60, 892–896 (2003).
- Morales E. et al. Association of early-life exposure to household gas appliances and indoor nitrogen dioxide with cognition and attention behavior in preschoolers. Am. J. Epidemiol. 169, 1327–1336 (2009).
- Wang S. et al. Association of traffic-related air pollution with children’s neurobehavioral functions in Quanzhou, China. Environ. Health. Perspect. 117, 1612–1618 (2009).
- Gatto N. M. et al. Components of air pollution and cognitive function in middle-aged and older adults in Los Angeles. Neurotoxicology. 40, 1–7 (2014).
- Liu P. et al. A survey of the psychological state and neurobehavioral function of traffic policemen [in Chinese]. China. Occup. Med. 27, 7–9 (2001).
- Wang Y. S., Zhang H. Y. & Chen W. J. Investigation of nerve behavior function of drivers and busmen [in Chinese]. Anhui.J. Prev. Med. 8, 315–353 (2002).
- Grundman M. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch. Neurol. 61, 59–66 (2004).
- Maioli F. et al. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch. Gerontol. Geriatr. 44, 233–241 (2007).
- Pujadas L. et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease. Nat. Commun. 5, 3443 (2014).
- Garcia-Alloza M. et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516–524 (2006).
- Yang H. & Chen C. Cyclooxygenase-2 in synaptic signaling. Curr. Pharm. Des. 14, 1443–1451 (2008).
- Lima I. V. et al. Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators. Inflamm. 2012, 1–13 (2012).
- Rao J. S., Rapoport S. I. & Kim H. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer’s disease brain. Transl. Psychiatry. 1, e31 (2011).
- Dajani E. Z. & Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J. Physiol. Pharmacol. 2, 117–133 (2008).
- Xu J. & Chen C. Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist. 21, 152–168 (2015).
- Nomura D. K. et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 334, 809–813 (2011).
- Chen R. et al. Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease. Cell. Rep. 2, 1329–1339 (2012).
- Piro J. R. et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell. Rep. 1, 617–623 (2012).
- Zhang J. & Chen C. Endocannabinoid 2-Arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283, 22601–22611 (2008).
- Hoshino T. et al. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J. Biol. Chem. 282, 32676–32688 (2007).
- Ozone Monitoring Instrument. Daily OMI tropospheric NO2 (air pollution and air quality) satellite measurements over other regions in the world.
- Alzheimer’s Disease International, Alzheimer’s Australia. Dementia in the Asia Pacific Region. Alzheimer’s Disease International (ADI), London (2014).
- Jack C. R. et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet. Neurol. 12, 207–216 (2013).
- Calderón-Garcidueñas L. et al. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. Toxicol Pathol. 36, 289–310 (2008).
- Ji X., Han M., Yun Y., Li G. & Sang N. Acute nitrogen dioxide (NO2) exposure enhances airway inflammation via modulatingTh1/Th2 differentiation and activating JAK-STAT pathway. Chemosphere. 120, 722–728 (2015).
- Li H., Han M., Guo L., Li G. & Sang N. Oxidative stress, endothelial dysfunction and inflammatory response in rat heart to NO2 inhalation exposure. Chemosphere. 82, 1589–1596 (2011).
- Yan W., Ji X., Shi J., Li G. & Sang N. Acute nitrogen dioxide inhalation induces mitochondrial dysfunction in rat brain. Environ. Res. 138, 416–424 (2015).
- Sang N. & Chen C. Lipid signaling and synaptic plasticity. Neuroscientist. 12, 425–434 (2006).
- Combrinck M. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 77, 85–88 (2006).
- Zhen G. et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer’s disease. Neurobiol. Aging. 33, 2215–2219 (2012).
- Tonne C., Elbaz A., Beevers S. & Singh-Manoux A. Traffic-related air pollution in relation to cognitive function in older adults. Epidemiol. 25, 674–681 (2014).
- Campbell A. et al. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology. 26, 133–140 (2005).
- Vlad S. C., Miller D. R., Kowall N. W. & Felson D. T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 70, 1672–1677 (2008).
- Richard O. et al. The vascular effects of COX-2 selective inhibitors. Aust. Prescr. 27, 142–145 (2004).
- Alger B. E. Endocannabinoid signaling in neural plasticity. Curr. Top. Behav. Neurosci. 1, 1141–1172 (2009).
- Chen X., Zhang J. & Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience. 178, 159–168 (2011).
- Du H., Chen X., Zhang J. & Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br. J. Pharmacol. 163, 1533–1549 (2011).
- Querfurth H. W. & LaFerla F. M. Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 (2010).